BioSpace News Archive

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results and a corporate update for the first quarter ended March 31, 2020.

PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2020 and provides a business update

Personalis, Inc., a leader in advanced genomics for cancer, reported financial results for the first quarter ended March 31, 2020.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported financial results for the first quarter of 2020.

Equillium, Inc. announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., chief medical officer, will participate in a fireside discussion at 2020 RBC Capital Markets Virtual Global Healthcare Conference on Wednesday, May 20, 2020.

Coherus BioSciences, Inc., reviewed corporate events and reported financial results for the quarter ended March 31, 2020.

Trovagene, Inc., a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, announced company highlights and financial results for the first quarter ended March 31, 2020.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, announced results for the first quarter of 2020 in addition to providing an update on the company’s recent activities.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, reported financial results and provided business updates for the quarter ended March 31, 2020.